AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Mereo BioPharma Group PLC ADR (NASDAQ:MREO)
0.3094 USD
-0.001 0.194%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.31 |
|---|---|
| Change | -0.001 0.194% |
| 52 W H/L (in USD) | 4.360/0.991 |
| EBITDA (in USD) | -24.986M |
| PE Ratio | -- |
| Volume | 1440204 |
| Diluted Eps TTM | -0.17 |
| Total Assets (in USD) | 66.499M |
|---|---|
| Total Liabilities (in USD) | 15.962M |
| Revenue TTM (in USD) | 10M |
| Cash (in USD) | 57.421M |
| Market Cap (in USD) | 469.915 M |
| Revenue Per Share TTM | 0.074 |
| Gross Profit TTM (in USD) | 0.936M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Employees: 33
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Denise Scots-Knight Ph.D. | Co-Founder, CEO & Exec. Director | 1959 |
| 2. | Mr. Charles Sermon | Co-Founder, Gen. Counsel & Company Sec. | 1969 |
| 3. | Dr. Alastair MacKinnon M.D., MBBS | Co-Founder and Chief of Portfolio & Pipeline Strategy | 1970 |
| 4. | Dr. John P. Richard M.B.A., MBA | Co-Founder & Chief Bus. Officer | 1957 |
| 5. | Ms. Christine Fox CPA | Chief Financial Officer | 1981 |
| 6. | Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | 1952 |
| 7. | Dr. Jackie Parkin | Therapy Area Head of Respiratory Endocrinology | NA |
| 8. | Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | 1971 |
| 9. | Dr. Suba Krishnan | Sr. VP of Clinical Devel. | NA |
| 10. | Dr. Fiona Bor | Head of Intellectual Property | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -36.093M | 14.241M | -166.45M | -41.118M | -37.306M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -34.196M | 12.725M | -163.628M | -34.844M | -32.029M |
| Selling General Administrative | 19.543M | 15.933M | 21.222M | 15.909M | 12.505M |
| Gross Profit | 2.443M | 18.556M | -15.954M | -23.73M | -22.704M |
| Reconciled Depreciation | 0.727M | 0.642M | 1.599M | 1.577M | 0.038M |
| Ebit | -43.569M | -20.936M | -37.569M | -39.517M | -34.902M |
| Ebitda | -42.062M | -20.314M | -37.525M | -37.563M | -34.864M |
| Depreciation And Amortization | 1.507M | 0.622M | 0.044M | 1.954M | 0.038M |
| Operating Income | -43.569M | -20.936M | -37.569M | -39.517M | -35.208M |
| Other Operating Expenses | 43.569M | 57.4M | 37.569M | 39.517M | 35.208M |
| Interest Expense | 3.361M | 4.001M | 6.383M | 3.496M | 2.361M |
| Tax Provision | -1.897M | 1.516M | -2.822M | -6.274M | -5.277M |
| Interest Income | 0.696M | 0.001M | 0.005M | 0.183M | 0.307M |
| Net Interest Income | -2.665M | -4.021M | -6.339M | -3.575M | -2.032M |
| Income Tax Expense | -1.897M | 1.516M | -2.822M | -6.274M | -5.277M |
| Total Revenue | 1.507M | 36.464M | 0.393M | -0.122M | 0M |
| Total Operating Expenses | 44.505M | 39.492M | 21.222M | 15.909M | 12.505M |
| Cost Of Revenue | -0.936M | 17.908M | 16.347M | 23.608M | 22.704M |
| Total Other Income Expense Net | 7.476M | 35.177M | -128.881M | -1.601M | -0.044M |
| Net Income From Continuing Ops | -34.196M | 12.725M | -163.628M | -34.844M | -32.029M |
| Net Income Applicable To Common Shares | -34.196M | 12.725M | -163.628M | -34.844M | -32.029M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 66.499M | 88.078M | 126.417M | 62.947M | 86.449M |
| Intangible Assets | 1.089M | 24.116M | 24.564M | 31.648M | 44.456M |
| Other Current Assets | 1.36M | - | 3.207M | 2.026M | 2.404M |
| Total Liab | 15.962M | 26.21M | 38.415M | 77.918M | 46.193M |
| Total Stockholder Equity | 50.537M | 61.868M | 88.002M | -14.971M | 40.256M |
| Other Current Liab | 0.03M | 10.048M | 1.269M | 4.596M | 0.354M |
| Common Stock | 2.775M | 1.875M | 1.755M | 1.017M | 0.294M |
| Capital Stock | 2.775M | 1.875M | 1.755M | 1.017M | 0.294M |
| Retained Earnings | -419.63M | -331.164M | -296.968M | -309.693M | -146.065M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | - | - |
| Cash | 57.421M | 56.334M | 94.296M | 23.469M | 16.347M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 9.486M | 24.677M | 12.541M | 8.565M | 29.878M |
| Current Deferred Revenue | 6.458M | - | 8.365M | - | 5.447M |
| Net Debt | -51.469M | -43.561M | -77.536M | -5.533M | 16.069M |
| Short Term Debt | 0.652M | 11.551M | 0.622M | 0.636M | 17.725M |
| Short Long Term Debt | - | 11.085M | - | - | 15.139M |
| Short Long Term Debt Total | 5.952M | 12.773M | 16.76M | 17.936M | 32.416M |
| Other Stockholder Equity | 484.877M | 253.245M | 246.32M | 160.48M | 138.708M |
| Property Plant Equipment | - | 1.831M | 2.53M | 1.573M | 11.558M |
| Total Current Assets | 63.76M | 62.131M | 99.323M | 29.726M | 30.435M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | 0M |
| Net Receivables | 3.732M | 2.672M | 1.82M | 4.638M | 11.977M |
| Long Term Debt | 4.394M | - | 14.384M | 16.142M | 5.373M |
| Inventory | 1.247M | - | - | - | - |
| Accounts Payable | 2.346M | 3.078M | 2.285M | 3.333M | 6.352M |
| Accumulated Other Comprehensive Income | -17.485M | 137.912M | 136.895M | 133.225M | 47.319M |
| Non Currrent Assets Other | - | - | - | - | 11.558M |
| Non Current Assets Total | 2.739M | 25.947M | 27.094M | 33.221M | 56.014M |
| Capital Lease Obligations | 1.558M | 1.688M | 2.376M | 1.794M | 11.904M |
| Long Term Debt Total | - | - | - | - | 14.691M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 1.497M | -0.421M | 1.495M | 43.295M | 0.252M |
| Total Cashflows From Investing Activities | - | -0.421M | 1.495M | 43.295M | 0.252M |
| Total Cash From Financing Activities | -0.784M | 77.652M | 34.737M | -5.71M | -2.073M |
| Net Income | -36.093M | 14.241M | -166.45M | -41.118M | -37.306M |
| Change In Cash | -37.962M | 70.827M | 7.122M | -8.695M | -25.003M |
| Begin Period Cash Flow | 94.296M | 23.469M | 16.347M | 25.042M | 50.045M |
| End Period Cash Flow | 56.334M | 94.296M | 23.469M | 16.347M | 25.042M |
| Total Cash From Operating Activities | -38.82M | -5.239M | -28.341M | -45.931M | -23.137M |
| Depreciation | 0.727M | 0.642M | 1.599M | 1.577M | 0.038M |
| Other Cashflows From Investing Activities | - | 0.001M | 0.044M | 0.377M | 0.286M |
| Dividends Paid | 0M | 0M | 0M | 0M | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | - | 0M | 0M | -0.998M | -0.307M |
| Other Cashflows From Financing Activities | 0.153M | -0.188M | 36.489M | -2.5M | -2.04M |
| Capital Expenditures | 0.01M | 0.535M | 0.016M | 0.021M | 0.036M |
| Change In Working Capital | 1.821M | -1.845M | -3.41M | -7.666M | 2.408M |
| Other Non Cash Items | -9.137M | 13.409M | 5.225M | -0.429M | 1.918M |
| Free Cash Flow | -38.83M | -5.774M | -28.357M | -45.952M | -23.173M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | abrdn Healthcare Investors | 2 years ago | 560468 |
| 2. | Tema Obesity & Cardiometabolic ETF | 2 years ago | 494424 |
| 3. | Alger LIfe Sciences Innovation Composite | 2 years ago | 290413 |
| 4. | abrdn Life Sciences Investors | 2 years ago | 256841 |
| 5. | Tema Oncology ETF | 2 years ago | 152550 |
| 6. | Fidelity Nasdaq Composite Index | 2 years ago | 96630 |
| 7. | PMC Diversified Equity | 2 years ago | 55903 |
| 8. | Arctic Aurora Biotech Select N NOK Acc | 2 years ago | 52160 |
| 9. | Vanguard US Opportunities Ins USD Acc | 2 years ago | 44000 |
| 10. | ActivePassive International Equity ETF | 2 years ago | 40311 |
| 11. | Forefront Tiresias Strategy | 2 years ago | 33424 |
| 12. | JHVIT Health Sciences I | 2 years ago | 28300 |
| 13. | JHFunds2 Health Sciences NAV | 2 years ago | 28200 |
| 14. | T. Rowe Price Hlth Sci Eq Q | 2 years ago | 26900 |
| 15. | EQ/T. Rowe Price Health Sciences IB | 2 years ago | 19600 |
| 16. | PRIMECAP Odyssey Aggressive Growth | 2 years ago | 10000 |
| 17. | LUX IM Global Medtech HX | 2 years ago | 2200 |
| 18. | Northern Small Cap Core K | 2 years ago | 1007 |
| 19. | NT Quality SCC US Fund - L | 2 years ago | 619 |
| 20. | NT Quality Small Cap Core | 2 years ago | 619 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Goldman Sachs Group Inc | 2 years ago | 4047344 |
| 2. | Tejara Capital Ltd | 2 years ago | 3713129 |
| 3. | Rubric Capital Management LP | 2 years ago | 13552997 |
| 4. | Soleus Capital Management, L.P. | 2 years ago | 9777419 |
| 5. | Adage Capital Partners Gp LLC | 2 years ago | 9328739 |
| 6. | Mangrove Partners | 2 years ago | 8752893 |
| 7. | Rock Springs Capital Management LP | 2 years ago | 7983851 |
| 8. | Suvretta Capital Management, LLC | 2 years ago | 7370838 |
| 9. | 683 Capital Management LLC | 2 years ago | 6200000 |
| 10. | HHG PLC | 2 years ago | 5120573 |
| 11. | Alkeon Capital Management, LLC | 2 years ago | 4238100 |
| 12. | Clearline Capital LP | 2 years ago | 3326718 |
| 13. | Millennium Management LLC | 2 years ago | 2179135 |
| 14. | Renaissance Technologies Corp | 2 years ago | 1798009 |
| 15. | abrdn PLC | 2 years ago | 1551082 |
| 16. | T. Rowe Price Associates, Inc. | 2 years ago | 991971 |
| 17. | Dafna Capital Management LLC | 2 years ago | 778813 |
| 18. | Monaco Asset Management | 2 years ago | 676494 |
| 19. | Longwood Capital Partners LLC | 2 years ago | 397884 |
| 20. | Neos Investment Management, LLC | 2 years ago | 351905 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...